SGLT2 抑制剂对贫血的作用及其可能的临床影响
Aleix Cases1, Secundino Cigarrán2, José Luis Górriz3
1Servei de Nefrología, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Grupo de Anemia de la S.E.N., Spain.
Nefrologia
|April 11, 2024
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 改善红细胞的产生和铁代谢. 这种血红蛋白的增加与它们在2型糖尿病,心力衰竭和慢性病患者中的显著心脏和脏益处有关.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 是已确立的2型糖尿病,心力衰竭和慢性病的治疗方法.
- 通过SGLT2i增加的血红蛋白/血红素的初步观察被归因于血度.
- 新出现的证据表明,SGLT2i对红色素形成和铁代谢有积极的影响.
研究的目的:
- 审查SGLT2i增强红细胞形成的机制.
- 探索SGLT2i诱导的血红蛋白增加和心脏脏功效之间的联系.
- 阐明改善铁代谢在SGLT2i疗效中的作用.
主要方法:
- 对SGLT2i,红色素形成和心结局现有文献的综述.
- 对调查血红蛋白增加作为SGLT2i益处的一个因素的调解研究的分析.
- 讨论关于SGLT2i对红色素和铁路的影响的临床前和临床数据.
主要成果:
- SGLT2i增加了红色素水平,并刺激了红色素生成.
- 随着SGLT2i的使用,观察到铁代谢的改善,包括转激素的增加和肝激素的减少.
- 血红蛋白增加是SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.
结论:
- SGLT2i通过多种机制增强红色素形成,包括增加红色素和改善铁的可用性.
- 血红蛋白的升高是一个关键因素,有助于SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.SGLT2i.
- 了解这些机制可以进一步了解SGLT2i在心脏病的治疗潜力.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Factors Influencing Drug Absorption: Disease States and Pharmacology
508
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
508
Esophageal Varices-II: Clinical Features and Management
60
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
60
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
195
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182


